Gilead Sciences Inc. has taken to calling itself the leader in cell therapy since its launch of the CAR-T therapeutic Yescarta in 2017 and the company reported continued growth for the product on its third quarter earnings call Oct. 25, although the pace of growth has slowed.
Gilead’s Yescarta Growth Continues, But Momentum Slowed
Yescarta brought in $75m in the third quarter, up 10% sequentially, and well above the $20m tallied by competitor Kymriah. Gilead also saw continued HIV sales growth, with HCV sales in line with expectations.
